ClinicalTrials.gg
TerminatedNCT02480010Updated Sep 18, 2015Results posted

A Study of Pertuzumab in Participants With Prostate Cancer

A Phase 2 interventional study of Pertuzumab in Prostate Cancer, sponsored by Hoffmann-La Roche. Terminated at 11 sites in 6 countries. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2015-09-18.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated at the time of interim analysis since none of the participants showed a PSA response.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
19 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Prostatic Neoplasms by Hoffmann-La Roche — 3 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · Hoffmann-La Roche.

Enrollment
7th of 11
68 · median 84
Started
2003
with 1 other
Phase 2
3 of 11
1 open now
Registered
4th of 11
by date

Among the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche, this one is the 7th largest by enrollment, is one of 2 that started in 2003, is one of 3 in phase 2, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 11 studies in Prostatic Neoplasms by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 19 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Prostatic Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of intravenous (IV) pertuzumab in participants with hormone-refractory prostate cancer who have had no previous chemotherapy. Participants will be enrolled in two stages, the first (Cohort A) at a lower 420-mg dose and the second (Cohort B) at a higher 1050-mg dose based upon observations in Cohort A. Up to 50 participants may enter either cohort, for a total enrollment between 46 and 73 participants across 9 study centers.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults greater than (>) 18 years of age
  • documented adenocarcinoma of the prostate resistant to hormone therapy, progressed at 4 to 6 weeks following anti-androgen withdrawal
  • Prostate-specific antigen (PSA) values at least 20 ng/mL among those with asymptomatic or mildly symptomatic disease
  • performance status (KPS) at least 80 percent (%)
  • Castrate testosterone less than (\<) 50 ng/dL
  • at least 12 weeks
  • (LVEF) at least 50%
  • Adequate hematologic, hepatic, and renal function

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy, radionucleotide therapy, or immunotherapy for prostate cancer
  • Systemic within 1 month prior to Screening
  • Bisphosphonates within 6 months, narcotic analgesics within 2 weeks, or any agent with 28 days of study drug
  • Prior cumulative doxorubicin dose of > 360 mg/m\^2 or equivalent
  • Central nervous system (CNS) or pulmonary
  • Other , except adequately treated basal or squamous cell skin cancer
  • Significant cardiovascular disease
  • Active/uncontrolled concurrent illness or infection
  • Major surgery or traumatic injury within 4 weeks of study drug
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Pertuzumab 1050 mg (Cohort B)

    Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.

    Drug: Pertuzumab

  • Experimental
    Pertuzumab 420 mg (Cohort A)

    Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.

    Drug: Pertuzumab

Interventions

  • Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.

    Also known as: Perjeta

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Confirmed, Objective Response, Non-Response or Progressive Disease by PSA Levels Within the First 24 Weeks of Treatment With Pertuzumab

    Objective PSA response rate was determined according to Prostate Specific Antigen Working Group (PSAWG) guidelines. All participants achieving a drop in PSA of greater than or equal to (≥) 50 percent (%) from baseline (confirmed with a second value at least 4 weeks later) fulfilled the criteria of a PSA response. The confirmatory second value had to be at least 50% lower than baseline, but could be higher than the first drop in PSA. Confirmatory value could not be 50% higher compared to first drop in PSA. The date of response was the date the first 50% (or greater) decline was observed. Progressive disease (PD) was defined by a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which documented progressively increasing values. Non-response was defined as neither PD nor Response.

    Time frame: Screening, Every 3 weeks up to Week 24

Secondary outcomes

  1. Time to Disease Progression

    Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events. 1) PSA progression as defined by the PSAWG, 2) Evidence of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 3) One bone scan at least 6 months subsequent to baseline demonstrating 2 or more new skeletal lesions and 4) An event due to metastatic prostate cancer requiring intervention.

    Time frame: Screening, Every 3 weeks up to a maximum of 18 months

  2. Percentage of Participants With Objective Response (Complete Response [CR] or Partial Response [PR]) by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria

    Overall objective response by RECIST criteria (CR or PR) was to be defined for participants who had measurable disease at baseline or developed new lesions post-baseline. The longest diameter only for all target lesions was measured and the following responses recorded: CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter as compared to the baseline sum longest diameter.

    Time frame: Screening, Weeks 6, 12, 24, 36 and 48

  3. Time to Response

    Time to response was the date of the first documentation of PSA response.

    Time frame: Screening, Every 3 weeks for a maximum of 18 months

  4. Duration of Response According to PSA Levels

    Duration of PSA Response was measured from first 50% decline in PSA compared to baseline until the time at which there was an increase of ≥50% from the PSA nadir, provided the absolute increase was at least 5 nanograms per milliliter (ng/ml). The increase must have been confirmed by a second consecutive measurement that was at least 50% above the nadir.

    Time frame: Baseline, Every 3 weeks for a maximum of 18 months

  5. Duration of Response According to RECIST Criteria

    For participants with measurable disease, duration of response was defined as first documentation of tumor response, either a PR or CR, to first documentation of PD or death. Participants who never progressed or died were censored at their last tumor measurement.

    Time frame: Baseline, Weeks 6, 12, 24, 36 and 48

  6. Percentage of Participants Without Progression

    Disease progression was defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Non-progression included participants who had responded plus those who had not responded and not progressed within the first 3 cycles.

    Time frame: Screening, Weeks 3, 6, 9 and 12

  7. Time to Prostate Cancer Pain Progression

    Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events: 1) Opioid therapy, 2) Radiation therapy, 3) Glucocorticoid therapy, 4) Radionuclide therapy or 5) Chemotherapy.

    Time frame: Every 3 weeks up to a maximum of 18 weeks

  8. Overall Survival

    Overall survival was defined as the interval of time in weeks between start of treatment and day of death. Participants who did not die while being followed were censored at the last time that they were known to be alive.

    Time frame: Screening, Every 3 weeks up to a maximum of 18 months

  9. Time to Treatment Failure

    Time to Treatment Failure was time to the first documentation of progressive disease, day of death while on study (or 30 days after withdrawing from the trial) or day of early discontinuation due to toxicity (adverse events or abnormal laboratory value), refusal of treatment/refusing to cooperate/withdrawing consent, insufficient therapeutic response, or failure to return, whichever is earliest, after the start of treatment. Participants who did not experience any of the above events while on study were censored on the day of their last PSA or tumor measurement, whichever was later.

    Time frame: Every 3 weeks up to a maximum of 18 weeks

  10. Change From Baseline in Bone Alkaline Phosphatase

    Bone alkaline phosphatase (BAP) is the bone-specific isoform of alkaline phosphatase. Serum Bone alkaline phosphatase is used to measure osteoporosis and is measured as units per liter (u/L).

    Time frame: Screening, Weeks 6, 12, 24, 36 and 48

  11. Change From Baseline in N-Telopeptide

    In bone physiology, the N-terminal telopeptide (or more formally, amino-terminal collagen crosslinks, and known by the acronym NTX) is a telopeptide that can be used as a biomarker to measure the rate of bone turnover. NTX can be measured in the urine (uNTX) or serum (serum NTX).

    Time frame: Screening, Weeks 6, 12, 24, 36 and 48

  12. Area Under the Concentration Curve Extrapolated to Infinity (AUC0-Inf) of Pertuzumab

    The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as micrograms times days per milliliter (µg\*day/mL)

    Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1

  13. AUC to Last Measurable Concentration (AUC0-last) of Pertuzumab

    The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.

    Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1

  14. Maximum Plasma Concentration of Pertuzumab

    Cmax is the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. Cmax is measured as micrograms per mL (μg/mL).

    Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1

  15. Time to Maximum Plasma Concentration (Tmax) of Pertuzumab

    Cmax refers to the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. tmax is the time at which the Cmax is observed.

    Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1 and on Days 8 and 15, Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1

  16. Terminal Elimination Half-Life (t1/2) of Pertuzumab

    t1/2 is the time in days required for the concentration of the drug to reach half of its original value

    Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1

  17. Serum Clearance of Pertuzumab

    Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).

    Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1

  18. Volume of Distribution at Steady State of Pertuzumab

    The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.

    Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1

  19. Mean Residence Time (MRT) of Pertuzumab

    MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.

    Time frame: Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1

07

Results

Posted Sep 18, 2015
Limitations and caveats
The study was terminated at the time of interim analysis since none of the participants showed a PSA response.

Participant flow

Participant flow — Overall Study
MilestonePertuzumab 420 Milligrams (mg) - Cohort APertuzumab 1050 mg - Cohort B
Started3533
Completed00
Not completed3533
Withdrew: Adverse event31
Withdrew: Death10
Withdrew: Insufficient therapeutic response3129
Withdrew: Refused treatment03

Outcome measures

PrimaryPercentage of Participants With Confirmed, Objective Response, Non-Response or Progressive Disease by PSA Levels Within the First 24 Weeks of Treatment With Pertuzumab

Objective PSA response rate was determined according to Prostate Specific Antigen Working Group (PSAWG) guidelines. All participants achieving a drop in PSA of greater than or equal to (≥) 50 percent (%) from baseline (confirmed with a second value at least 4 weeks later) fulfilled the criteria of a PSA response. The confirmatory second value had to be at least 50% lower than baseline, but could be higher than the first drop in PSA. Confirmatory value could not be 50% higher compared to first drop in PSA. The date of response was the date the first 50% (or greater) decline was observed. Progressive disease (PD) was defined by a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which documented progressively increasing values. Non-response was defined as neither PD nor Response.

Time frame:
Screening, Every 3 weeks up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed, Objective Response, Non-Response or Progressive Disease by PSA Levels Within the First 24 Weeks of Treatment With Pertuzumab
percentage of participantsPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Objective response0.00.0
Non-response34.330.3
PD65.766.7
Missing0.03.0
SecondaryTime to Disease Progression

Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events. 1) PSA progression as defined by the PSAWG, 2) Evidence of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 3) One bone scan at least 6 months subsequent to baseline demonstrating 2 or more new skeletal lesions and 4) An event due to metastatic prostate cancer requiring intervention.

Time frame:
Screening, Every 3 weeks up to a maximum of 18 months
Reported as:
Median · weeks
Time to Disease Progression
weeksPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Time to Disease Progression5.6 (2.8 to 20.9)6.1 (2.7 to 17.9)
SecondaryPercentage of Participants With Objective Response (Complete Response [CR] or Partial Response [PR]) by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria

Overall objective response by RECIST criteria (CR or PR) was to be defined for participants who had measurable disease at baseline or developed new lesions post-baseline. The longest diameter only for all target lesions was measured and the following responses recorded: CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of the longest diameter as compared to the baseline sum longest diameter.

Time frame:
Screening, Weeks 6, 12, 24, 36 and 48

No measurements were reported for this outcome.

SecondaryTime to Response

Time to response was the date of the first documentation of PSA response.

Time frame:
Screening, Every 3 weeks for a maximum of 18 months

No measurements were reported for this outcome.

SecondaryDuration of Response According to PSA Levels

Duration of PSA Response was measured from first 50% decline in PSA compared to baseline until the time at which there was an increase of ≥50% from the PSA nadir, provided the absolute increase was at least 5 nanograms per milliliter (ng/ml). The increase must have been confirmed by a second consecutive measurement that was at least 50% above the nadir.

Time frame:
Baseline, Every 3 weeks for a maximum of 18 months

No measurements were reported for this outcome.

SecondaryDuration of Response According to RECIST Criteria

For participants with measurable disease, duration of response was defined as first documentation of tumor response, either a PR or CR, to first documentation of PD or death. Participants who never progressed or died were censored at their last tumor measurement.

Time frame:
Baseline, Weeks 6, 12, 24, 36 and 48

No measurements were reported for this outcome.

SecondaryPercentage of Participants Without Progression

Disease progression was defined as the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Non-progression included participants who had responded plus those who had not responded and not progressed within the first 3 cycles.

Time frame:
Screening, Weeks 3, 6, 9 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Without Progression
percentage of participantsPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Percentage of Participants Without Progression20.018.2
SecondaryTime to Prostate Cancer Pain Progression

Time to disease progression was defined by time in weeks from start of therapy to the onset of the earliest of the following events: 1) Opioid therapy, 2) Radiation therapy, 3) Glucocorticoid therapy, 4) Radionuclide therapy or 5) Chemotherapy.

Time frame:
Every 3 weeks up to a maximum of 18 weeks

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival was defined as the interval of time in weeks between start of treatment and day of death. Participants who did not die while being followed were censored at the last time that they were known to be alive.

Time frame:
Screening, Every 3 weeks up to a maximum of 18 months

No measurements were reported for this outcome.

SecondaryTime to Treatment Failure

Time to Treatment Failure was time to the first documentation of progressive disease, day of death while on study (or 30 days after withdrawing from the trial) or day of early discontinuation due to toxicity (adverse events or abnormal laboratory value), refusal of treatment/refusing to cooperate/withdrawing consent, insufficient therapeutic response, or failure to return, whichever is earliest, after the start of treatment. Participants who did not experience any of the above events while on study were censored on the day of their last PSA or tumor measurement, whichever was later.

Time frame:
Every 3 weeks up to a maximum of 18 weeks
Reported as:
Median · days
Time to Treatment Failure
daysPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Time to Treatment Failure6.1 (2.8 to 20.9)6.1 (2.7 to 17.9)
SecondaryChange From Baseline in Bone Alkaline Phosphatase

Bone alkaline phosphatase (BAP) is the bone-specific isoform of alkaline phosphatase. Serum Bone alkaline phosphatase is used to measure osteoporosis and is measured as units per liter (u/L).

Time frame:
Screening, Weeks 6, 12, 24, 36 and 48

No measurements were reported for this outcome.

SecondaryChange From Baseline in N-Telopeptide

In bone physiology, the N-terminal telopeptide (or more formally, amino-terminal collagen crosslinks, and known by the acronym NTX) is a telopeptide that can be used as a biomarker to measure the rate of bone turnover. NTX can be measured in the urine (uNTX) or serum (serum NTX).

Time frame:
Screening, Weeks 6, 12, 24, 36 and 48

No measurements were reported for this outcome.

SecondaryArea Under the Concentration Curve Extrapolated to Infinity (AUC0-Inf) of Pertuzumab

The area under the plot of plasma concentration of drug against time after drug administration is defined as the area under the curve (AUC). The AUC0-infinity is calculated from time 0 (prior to administration of medication) to infinity (the time of complete elimination of the drug). The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. AUC is measured as micrograms times days per milliliter (µg\*day/mL)

Time frame:
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Reported as:
Geometric mean · µg*day/mL
Area Under the Concentration Curve Extrapolated to Infinity (AUC0-Inf) of Pertuzumab
µg*day/mLPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Area Under the Concentration Curve Extrapolated to Infinity (AUC0-Inf) of Pertuzumab3488 ± 445097 ± 71
SecondaryAUC to Last Measurable Concentration (AUC0-last) of Pertuzumab

The AUC0-last is calculated from time 0 (prior to administration of medication) to last measured data point. The AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.

Time frame:
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Reported as:
Geometric mean · µg*day/mL
AUC to Last Measurable Concentration (AUC0-last) of Pertuzumab
µg*day/mLPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
AUC to Last Measurable Concentration (AUC0-last) of Pertuzumab2305 ± 222626 ± 28
SecondaryMaximum Plasma Concentration of Pertuzumab

Cmax is the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. Cmax is measured as micrograms per mL (μg/mL).

Time frame:
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Reported as:
Geometric mean · μg/mL
Maximum Plasma Concentration of Pertuzumab
μg/mLPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Maximum Plasma Concentration of Pertuzumab255 ± 23294 ± 24
SecondaryTime to Maximum Plasma Concentration (Tmax) of Pertuzumab

Cmax refers to the maximum (or peak) plasma concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered and prior to the administration of a second dose. tmax is the time at which the Cmax is observed.

Time frame:
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1 and on Days 8 and 15, Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Reported as:
Geometric mean · days
Time to Maximum Plasma Concentration (Tmax) of Pertuzumab
daysPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Time to Maximum Plasma Concentration (Tmax) of Pertuzumab0.073 ± 110.074 ± 6
SecondaryTerminal Elimination Half-Life (t1/2) of Pertuzumab

t1/2 is the time in days required for the concentration of the drug to reach half of its original value

Time frame:
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Reported as:
Geometric mean · days
Terminal Elimination Half-Life (t1/2) of Pertuzumab
daysPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Terminal Elimination Half-Life (t1/2) of Pertuzumab13.7 ± 3919.3 ± 69
SecondarySerum Clearance of Pertuzumab

Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It is measured as milliliters per day (mL/day).

Time frame:
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Reported as:
Geometric mean · mL/day
Serum Clearance of Pertuzumab
mL/dayPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Serum Clearance of Pertuzumab270 ± 29253 ± 35
SecondaryVolume of Distribution at Steady State of Pertuzumab

The volume of distribution at steady state (Vss), also known as apparent volume of distribution, is a pharmacological, theoretical volume that the total amount of administered drug would have to occupy (if it were uniformly distributed), to provide the same concentration as it currently is in blood plasma.

Time frame:
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Reported as:
Geometric mean · mL
Volume of Distribution at Steady State of Pertuzumab
mLPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Volume of Distribution at Steady State of Pertuzumab4452 ± 265227 ± 24
SecondaryMean Residence Time (MRT) of Pertuzumab

MRT is the average time that pertuzumab is present in the systemic circulation and is measured in days.

Time frame:
Cycles 1 and 2 (Weeks 3 and 6): predose (immediately prior to infusion) and within 15 minutes following the end of the infusion on Day 1, Day 8, and Day 15. Cycle 3 (Week 9) and beyond: predose and within 15 minutes following end of infusion on Day 1
Reported as:
Geometric mean · days
Mean Residence Time (MRT) of Pertuzumab
daysPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Mean Residence Time (MRT) of Pertuzumab18.1 ± 4225.7 ± 77

Adverse events

Collected over Adverse Events were recorded from the date of Screening until 7 weeks after the last infusion of study treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab 420 mg - Cohort A—9/35 (25.7%)28/35 (80%)
Pertuzumab 1050 mg - Cohort B—6/33 (18.2%)24/33 (72.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
Urinary retentionRenal and urinary disorders3/350/33
Abdominal PainGastrointestinal disorders0/351/33
HemastemisisGastrointestinal disorders0/351/33
Ileus ParalyticGastrointestinal disorders0/351/33
NauseaGastrointestinal disorders0/351/33
Central Line InfectionInfections and infestations0/351/33
SepsisInfections and infestations0/351/33
Metastatic PainNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/351/33
Deep Vein ThrombosisVascular disorders0/351/33
Renal FailureRenal and urinary disorders1/350/33
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort B
DiarrhoeaGastrointestinal disorders18/3517/33
FatigueGeneral disorders15/354/33
NauseaGastrointestinal disorders11/352/33
AnorexiaMetabolism and nutrition disorders8/352/33
BackpainMusculoskeletal and connective tissue disorders5/352/33
RhinorrhoeaRespiratory, thoracic and mediastinal disorders3/354/33
Pain in ExtremityMusculoskeletal and connective tissue disorders3/354/33
RashSkin and subcutaneous tissue disorders3/354/33
VomitingGastrointestinal disorders4/350/33
CoughRespiratory, thoracic and mediastinal disorders4/350/33

Baseline characteristics

Intent-to-Treat (ITT) population consisted of all participants enrolled and who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Pertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort BTotal
Mean70.8 ± 7.4571.2 ± 6.0171.0 ± 6.74
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab 420 mg - Cohort APertuzumab 1050 mg - Cohort BTotal
Female000
Male353368
08

Study locations

11 sites
  • Lyon, 69008, France
  • Montpellier, 34298, France
  • Berlin, 12203, Germany
  • Parma, 43100, Italy
  • Roma, 00152, Italy
  • Rotterdam, 3075 EA, Netherlands
  • Barcelona, 08035, Spain
  • Valencia, 46009, Spain
  • Cardiff, CF14 2TL, United Kingdom
  • Sutton, SM2 5PT, United Kingdom
  • Weston Super Mare, BS23 4TQ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003, a primary completion of Sep 2005 and a completion of Sep 2005. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 10 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2015
First posted
Jun 24, 2015
Start
Sep 2003
Primary completionActual
Sep 2005
CompletionActual
Sep 2005
Results first posted
Sep 18, 2015
Last update
Sep 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02480010
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 24, 2015
Start date
Sep 2003
Primary completion
Sep 2005
Completion
Sep 2005
Results posted
Sep 18, 2015
Last update
Sep 18, 2015

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion